Mirae Asset Global Investments (Hong Kong) Limited has introduced a new ETF called the Global X China MedTech ETF (2841), which has been listed on the Hong Kong Stock Exchange. This ETF provides investors with access to Chinese companies operating in the medical technology sector, specializing in medical equipment, devices, and consumables.
The launch of this thematic ETF expands Mirae Asset’s range of investment products that focus on long-term disruptive trends. Given China’s rapidly growing medical device market, driven by an aging population, there are expected growth opportunities in the MedTech sector. It is projected to expand from RMB 1.2 trillion in 2022 to RMB 3.5 trillion by 2030, reflecting a compound annual growth rate (CAGR) of 14%.
Investors in the Global X China MedTech ETF can gain diversified exposure to various subsectors within the industry, including medical equipment, consumables, in-vitro diagnostics, and consumer medtech.
Mr. Wanyoun CHO, Chief Executive Officer of Mirae Asset Global Investments (Hong Kong) Limited, expressed enthusiasm about expanding their thematic ETF suite to target growth opportunities in the Chinese market. As Chinese innovators redefine the domestic, regional, and global economy, this ETF offers a unique opportunity for investors to participate in this dynamic market.